CRISPR Therapeutics AG
Viés de alta

No brainer alpha at a cheap price

1) Crisper has a lot of cash on hand to survive through tightening of QE and fund pipeline without dilution
2) Potential takeover by VRTX or other compamy at current prices VERY possible.

Aviso legal